TOTAL: $454.3M | ||||
Company | Location | Date | Amt. (M) | Details |
Anaphore Inc. | La Jolla, Calif. | 5/13 | $13 | Anaphore raised $13M to top off its original $25M Series A financing it closed on in January; SR One and Merck Serono Ventures invested in the extension, as did Aravis Venture |
Applied Genetic Technologies Corp. | Gainesville, Fla. | 5/1 | $11.8 | Applied Genetic raised $11.8M in a round led by InterWest Partners; other participants were Intersouth Partners and MedImmune Ventures Inc. |
Aragon Pharmaceuticals | La Jolla, Calif. | 5/20 | $8 | Aragon raised $8M in a Series A financing led by the Column Group and OrbiMed Advisors |
Avid Radio-pharmaceuticals Inc. | Philadelphia | 5/21 | $34.5 | Avid raised $34.5M in a Series D led by Alta Partners; other investors were AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group LLC and BioAdvance |
Calistoga Pharmaceuticals Inc. | Seattle | 5/5 | $30 | Calistoga raised $30M in a Series B round from Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners |
Cempra Pharmaceuticals Inc. | Research Triangle Park, N.C. | 5/14 | $46 | Cempra raised $46M in a Series C financing round led by Quaker BioVentures; other investors were Devon Park Bioventures, Aisling Capital, Intersouth Partners, Wistar Morris III and Teacher's Private Capital |
Clovis Oncology Inc. | Boulder, Colo. | 5/21 | $145 | Clovis raised $145M in start-up funds from Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures and ProQuest Investments |
Elixir Pharmaceuticals Inc. | Cambridge, Mass. | 5/19 | $12 | Elixir raised $12M in a financing led by MPM Capital and Physic Ventures, and included ARCH Venture Partners, Oxford Bioscience Partners and the Omega Fund |
NanoTherapies LLC (subsidiary of Keystone Nano Inc.) | Boalsburg, Pa. | 5/12 | ND | Cancer Therapeutics Inc. signed a letter of intent to acquire a minority ownership share of NanoTherapies in an equity transaction |
NovImmune SA | Plan-Les-Ouates, Switzerland | 5/11 | CHF62.5 ($56.5) |
NovImmune raised $56.5M in a financing led by BZ Bank AG |
PlexPress | Los Altos, Calif. | 5/12 | $2.75 | PlexPress closed a $2.75M seed round from Conor Technology Fund I, Veraventure, Helsinki University Fund and VTT |
Proteon Therapeutics Inc. | Waltham, Mass. | 5/28 | $12 | Proteon completed a second closing of its Series B equity financing, bringing the total raised to $50M; investors were Bessemer Venture Partners and Devon Park Bioventures |
Sagent Pharmaceuticals Inc. | Schaumburg, Ill. | 5/21 | $30 | Sagent raised $30M in a second Series A financing led by Vivo Ventures |
Sirona Biochem Corp. | Vancouver, British Columbia | 5/4 | $0.75 | Sirona raised $751,975 from TFChem SARI in exchange for 5M units at 15 cents each |
Tokai Pharmaceuticals | Cambridge, Mass. | 5/8 | $22 | Tokai closed a $22M Series D round led by Novartis Venture Fund; Apple Tree Partners also invested in the round |
VaxInnate Corp. | Cranbury, N.J. | 5/6 | $30 | VaxInnate raised $30M in a Series D financing led by new investor the Wellcome Trust; other investors were New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Ventures |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed. |